A recent study analyzing over 110,000 women discovered that those taking GLP-1 drugs—popular medications for weight loss and diabetes—had around a 30% lower chance of developing breast cancer, offering promising insights into potential cancer prevention.
- GLP-1 drugs linked to 30% lower breast cancer incidence
- Study reviewed data from more than 110,000 women
- Clinical trials planned to explore prevention potential
What happened
Researchers analyzed electronic health records of 111,646 women with a body mass index of 25 or higher who underwent breast imaging between 2022 and 2025. Among them, roughly 13.7% were prescribed GLP-1 medications like Ozempic and Wegovy. The study found that these women had significantly lower odds of developing breast cancer compared to those not taking the drugs, with reductions around 30% in both full and matched group analyses.
The study was observational and did not differentiate between individual GLP-1 medications or treatment durations, nor did it account for genetic risk or cancer stages. Despite these limitations, the consistent findings across large groups highlight the potential importance of these drugs as a novel factor in breast cancer research.
Why it feels good
These findings open an encouraging new chapter in cancer prevention by suggesting that widely used medications for diabetes and weight management might have additional benefits beyond their original purposes. Since breast cancer affects millions worldwide, a widely accessible preventive tool could have a major public health impact.
Experts emphasize that while the results are promising, only carefully designed clinical trials can determine whether these drugs actively reduce cancer risk. The study has energized researchers to explore how GLP-1 drugs influence biological pathways linked to cancer development, which may ultimately lead to innovative prevention strategies.
What to enjoy or watch next
Upcoming multisite clinical trials will focus on assessing the preventive effects of GLP-1 medications in women at high risk for breast cancer, including those with prior breast cancer history. These well-controlled studies will help clarify whether these drugs can be safely and effectively used to reduce cancer incidence.
Meanwhile, ongoing research may shed light on which specific aspects of GLP-1 medications impact breast cancer biology. Patients and healthcare providers should stay informed as this promising research develops, keeping an eye on new findings that could inform future treatment and prevention guidelines.